A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

Henk M Lokhorst, Bronno van der Holt, Sonja Zweegman, Edo Vellenga, Sandra Croockewit, Marinus H. van Oers, Peter von dem Borne, Pierre Wijermans, M Ron Schaafsma, Okke de Weerdt, Shulamiet Wittebol, Michel Delforge, Henriette Berenschot, Gerard M. Bos, Kon-Siong G. Jie, Harm Sinnige, Marinus van Marwijk-Kooy, Peter Joosten, Monique C. Minnema, Rianne van AmmerlaanPieter Sonneveld

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1113-1120
JournalBlood
Volume115
Issue number6
DOIs
Publication statusPublished - 11 Feb 2010

Cite this

Lokhorst, H. M., van der Holt, B., Zweegman, S., Vellenga, E., Croockewit, S., van Oers, M. H., Borne, P. V. D., Wijermans, P., Schaafsma, M. R., de Weerdt, O., Wittebol, S., Delforge, M., Berenschot, H., Bos, G. M., Jie, K-S. G., Sinnige, H., van Marwijk-Kooy, M., Joosten, P., Minnema, M. C., ... Sonneveld, P. (2010). A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood, 115(6), 1113-1120. https://doi.org/10.1182/blood-2009-05-222539